Nascent Biotech Inc. (NBIO)

[budfoxfun]

$NBIO The company's Phase 1 study on brain cancer emerges out of many years of research and background due diligence.
As noted above, NBIO's top asset is Pritumumab, which targets brain, lung, breast, and pancreatic cancer. PTB is a natural human antibody that binds to Cell surface Vimentin (also referred to as ectodomain vimentin), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy that seeks out cancer cells without damaging healthy cells.
If we look around the corner at value upon commercialization, the total addressable market ("TAM") the company is targeting with its initial brain cancer research program is set to surpass $4 billion over the next decade and a half.